From the impact of Obamacare to cutting edge research, biotech buyouts to FDA decisions, The Motley Fool's health care team sits down each week to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about the coming trend of penalizing unhealthy employees, the importance of drug branding, the avian flu outbreak, one stock investors need to watch, and more.
In the segment below, health care analyst Max Macaluso discusses how allergy season taught him a new lesson about Merck's (MRK -0.05%) over-the-counter allergy drug Claritin and the marketing practices of big pharma companies.
The relevant video segment can be found between 1:44 and 3:17.
